These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

248 related articles for article (PubMed ID: 30153492)

  • 1. Allocation to Matched Related or Unrelated Donor Results in Similar Clinical Outcomes without Increased Risk of Failure to Proceed to Transplant among Patients with Acute Myeloid Leukemia: A Retrospective Analysis from the Time of Transplant Approval.
    Rodríguez-Arbolí E; Márquez-Malaver FJ; Rodríguez-Torres N; Caballero-Velázquez T; Escamilla-Gómez V; Calderón-Cabrera C; Falantes-González JF; Solé-Rodríguez M; García-Ramírez P; Moya-Arnao M; Carreras E; Espigado-Tocino I; Pérez-Simón JA
    Biol Blood Marrow Transplant; 2019 Jan; 25(1):183-190. PubMed ID: 30153492
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Use of matched unrelated donors compared with matched related donors is associated with lower relapse and superior progression-free survival after reduced-intensity conditioning hematopoietic stem cell transplantation.
    Ho VT; Kim HT; Aldridge J; Liney D; Kao G; Armand P; Koreth J; Cutler C; Ritz J; Antin JH; Soiffer RJ; Alyea EP
    Biol Blood Marrow Transplant; 2011 Aug; 17(8):1196-204. PubMed ID: 21193054
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Poor outcome with nonmyeloablative conditioning regimen before cord blood transplantation for patients with high-risk acute myeloid leukemia compared with matched related or unrelated donor transplantation.
    Devillier R; Harbi S; Fürst S; Crocchiolo R; El-Cheikh J; Castagna L; Etienne A; Calmels B; Lemarie C; Prebet T; Granata A; Charbonnier A; Rey J; Chabannon C; Faucher C; Vey N; Blaise D
    Biol Blood Marrow Transplant; 2014 Oct; 20(10):1560-5. PubMed ID: 24933658
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The impact of HLA-matching on reduced intensity conditioning regimen unrelated donor allogeneic stem cell transplantation for acute myeloid leukemia in patients above 50 years-a report from the EBMT acute leukemia working party.
    Rubio MT; Savani BN; Labopin M; Polge E; Niederwieser D; Ganser A; Schwerdtfeger R; Ehninger G; Finke J; Renate A; Craddock C; Kröger N; Hallek M; Jindra P; Mohty M; Nagler A
    J Hematol Oncol; 2016 Aug; 9(1):65. PubMed ID: 27488518
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Allogeneic hematopoietic stem cell transplantation in adult acute lymphocytic leukemia: impact of donor source on survival.
    Kumar P; Defor TE; Brunstein C; Barker JN; Wagner JE; Weisdorf DJ; Burns LJ
    Biol Blood Marrow Transplant; 2008 Dec; 14(12):1394-400. PubMed ID: 19041062
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Long-term outcomes of HLA-matched sibling compared with mismatched related and unrelated donor hematopoietic stem cell transplantation for chronic phase chronic myelogenous leukemia: a single institution experience in China.
    Liu QF; Xu XJ; Chen YK; Sun J; Zhang Y; Fan ZP; Xu D; Jiang QL; Wei YQ; Huang F; Feng R; Liu XL; Xu B; Meng FY
    Ann Hematol; 2011 Mar; 90(3):331-41. PubMed ID: 20872002
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparable Outcomes After Alternative and Matched Sibling Donor Hematopoietic Stem Cell Transplantation and the Role of Molecular Measurable Residual Disease for Acute Myeloid Leukemia in Elderly Patients.
    Cho BS; Yahng SA; Min GJ; Park S; Park SS; Shin SH; Jeon YW; Yoon JH; Lee SE; Eom KS; Kim YJ; Lee S; Min CK; Cho SG; Kim DW; Lee JW; Kim M; Kim Y; Kim HJ
    Transplant Cell Ther; 2021 Sep; 27(9):774.e1-774.e12. PubMed ID: 34082159
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [A comparative study of unrelated donor and matched-sibling donor allogeneic hematopoietic stem cell transplantation in children and adolescents with acquired severe aplastic anemia].
    Zhou J; Fu YW; Liang LJ; Wang Q; Han LJ; Zu YL; Zhang Y; Zhu XH; Yu FK; Fang BJ; Wei XD; Song YP
    Zhonghua Nei Ke Za Zhi; 2016 Dec; 55(12):927-931. PubMed ID: 27916046
    [No Abstract]   [Full Text] [Related]  

  • 9. [Autologous versus unrelated donor stem cell transplantation for adults with primary acute myeloid leukemia in first remission].
    Yao JF; Zhang GX; Yang DL; He Y; Wei JL; Zhai WH; Jiang EL; Zhang RL; Feng SZ; Han MZ
    Zhonghua Xue Ye Xue Za Zhi; 2020 May; 41(5):365-372. PubMed ID: 32536132
    [No Abstract]   [Full Text] [Related]  

  • 10. Cytomegalovirus Reactivation after Allogeneic Hematopoietic Stem Cell Transplantation is Associated with a Reduced Risk of Relapse in Patients with Acute Myeloid Leukemia Who Survived to Day 100 after Transplantation: The Japan Society for Hematopoietic Cell Transplantation Transplantation-related Complication Working Group.
    Takenaka K; Nishida T; Asano-Mori Y; Oshima K; Ohashi K; Mori T; Kanamori H; Miyamura K; Kato C; Kobayashi N; Uchida N; Nakamae H; Ichinohe T; Morishima Y; Suzuki R; Yamaguchi T; Fukuda T
    Biol Blood Marrow Transplant; 2015 Nov; 21(11):2008-16. PubMed ID: 26211985
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Equivalent survival for sibling and unrelated donor allogeneic stem cell transplantation for acute myelogenous leukemia.
    Moore J; Nivison-Smith I; Goh K; Ma D; Bradstock K; Szer J; Durrant S; Schwarer A; Bardy P; Herrmann R; Dodds A
    Biol Blood Marrow Transplant; 2007 May; 13(5):601-7. PubMed ID: 17448920
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparable survival for pediatric acute myeloid leukemia with poor-risk cytogenetics following chemotherapy, matched related donor, or unrelated donor transplantation.
    Kelly MJ; Horan JT; Alonzo TA; Eapen M; Gerbing RB; He W; Lange BJ; Parsons SK; Woods WG
    Pediatr Blood Cancer; 2014 Feb; 61(2):269-75. PubMed ID: 23955900
    [TBL] [Abstract][Full Text] [Related]  

  • 13. WT1 Measurable Residual Disease Assay in Patients With Acute Myeloid Leukemia Who Underwent Allogeneic Hematopoietic Stem Cell Transplantation: Optimal Time Points, Thresholds, and Candidates.
    Cho BS; Min GJ; Park SS; Shin SH; Yahng SA; Jeon YW; Yoon JH; Lee SE; Eom KS; Kim YJ; Lee S; Min CK; Cho SG; Kim DW; Lee JW; Kim M; Kim Y; Kim HJ
    Biol Blood Marrow Transplant; 2019 Oct; 25(10):1925-1932. PubMed ID: 31173897
    [TBL] [Abstract][Full Text] [Related]  

  • 14. High prognostic value of pre-allogeneic stem cell transplantation minimal residual disease detection by WT1 gene expression in AML transplanted in cytologic complete remission.
    Candoni A; De Marchi F; Zannier ME; Lazzarotto D; Filì C; Dubbini MV; Rabassi N; Toffoletti E; Lau BW; Fanin R
    Leuk Res; 2017 Dec; 63():22-27. PubMed ID: 29096332
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The superiority of allogeneic hematopoietic stem cell transplantation from unrelated donor over chemotherapy for adult patients with high-risk acute lymphoblastic leukemia in first remission.
    Wang L; Wang Y; Tang W; Dou HB; Shan JH; Hu J
    Int J Hematol; 2013 Nov; 98(5):569-77. PubMed ID: 24078372
    [TBL] [Abstract][Full Text] [Related]  

  • 16. HLA-Matched Sibling versus Unrelated versus Haploidentical Related Donor Allogeneic Hematopoietic Stem Cell Transplantation for Patients Aged Over 60 Years with Acute Myeloid Leukemia: A Single-Center Donor Comparison.
    Devillier R; Legrand F; Rey J; Castagna L; Fürst S; Granata A; Charbonnier A; Harbi S; d'Incan E; Pagliardini T; Faucher C; Lemarie C; Saillard C; Calmels B; Mohty B; Maisano V; Weiller PJ; Chabannon C; Vey N; Blaise D
    Biol Blood Marrow Transplant; 2018 Jul; 24(7):1449-1454. PubMed ID: 29448057
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparing outcomes of matched related donor and matched unrelated donor hematopoietic cell transplants in adults with B-Cell acute lymphoblastic leukemia.
    Segal E; Martens M; Wang HL; Brazauskas R; Weisdorf D; Sandmaier BM; Khoury HJ; de Lima M; Saber W
    Cancer; 2017 Sep; 123(17):3346-3355. PubMed ID: 28452054
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Association of Persistent Minimal Residual Disease with Poor Outcomes of Patients with Acute Myeloid Leukemia Undergoing Allogeneic Hematopoietic Stem Cell Transplantation.
    Liu J; Zhao XS; Liu YR; Xu LP; Zhang XH; Chen H; Chen YH; Wang FR; Han W; Sun YQ; Yan CH; Tang FF; Mo XD; Liu KY; Fan QZ; Huang XJ; Chang YJ
    Chin Med J (Engl); 2018 Dec; 131(23):2808-2816. PubMed ID: 30511683
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prophylactic Donor Lymphocyte Infusion (DLI) Followed by Minimal Residual Disease and Graft-versus-Host Disease-Guided Multiple DLIs Could Improve Outcomes after Allogeneic Hematopoietic Stem Cell Transplantation in Patients with Refractory/Relapsed Acute Leukemia.
    Yan CH; Liu QF; Wu DP; Zhang X; Xu LP; Zhang XH; Wang Y; Huang H; Bai H; Huang F; Ma X; Huang XJ
    Biol Blood Marrow Transplant; 2017 Aug; 23(8):1311-1319. PubMed ID: 28483716
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Predictive value of pretransplantation molecular minimal residual disease assessment by WT1 gene expression in FLT3-positive acute myeloid leukemia.
    Candoni A; De Marchi F; Zanini F; Zannier ME; Simeone E; Toffoletti E; Chiarvesio A; Cerno M; Filì C; Patriarca F; Fanin R
    Exp Hematol; 2017 May; 49():25-33. PubMed ID: 28159598
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.